7 June 2019 - Report will be subject of Midwest CEPAC meeting in January 2020; open input now being accepted until 25 June 2019.

The Institute for Clinical and Economic Review (ICER) announced today that it plans to assess the comparative clinical effectiveness and value of treatments for acute migraine, including: two oral CGRP receptor antagonists, rimegepant (Biohaven) and ubrogepant (Allergan); and a 5-HT1f agonist lasmiditan (Eli Lilly). All three of these agents are under FDA review with an anticipated decision in the final quarter of 2019.

The report will be reviewed during a public meeting of the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC) in January 2020.

Read ICER announcement